I think if the long awaited licensing deal with ICL doesn’t contain an upfront payment like biotechs get when they licence out, or at least a placement to ICL to raise capital, then I think it will be a worry. The last thing the stock needs is another investor presentation, or another trip down under telling us nothing new or even another webcast. Just focus resources on delivering!
I think if the long awaited licensing deal with ICL doesn’t...
Add AJX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $17.18M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.2¢ | 1.0¢ | $4.674K | 429.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 7257398 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 437965 | 2 |
View Market Depth
| Last trade - 10.33am 20/06/2024 (20 minute delay) ? |
| AJX (ASX) Chart |